β-synuclein occurs in vivo in lipid-associated oligomers and forms hetero-oligomers with α-synuclein

Journal of Neurochemistry

Volumn 108, Issue 2, 2009, Pages 465-474

  Israeli, Eitan ^a   Sharon, Ronit ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

synuclein; synuclein; Polyunsaturated fatty acids; Protein oligomerization and aggregation

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; LINOLENIC ACID; OLIGOMER; POLYUNSATURATED FATTY ACID;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; MESENCEPHALON; MOLECULAR WEIGHT; MOUSE; NERVE CELL; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN STRUCTURE;

ALPHA-SYNUCLEIN; ANIMALS; BETA-SYNUCLEIN; BRAIN; CELL LINE, TRANSFORMED; CHROMATOGRAPHY, ION EXCHANGE; CYTOSOL; FATTY ACIDS, UNSATURATED; HUMANS; IMMUNOPRECIPITATION; LIPIDS; MACROMOLECULAR SUBSTANCES; MESENCEPHALON; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS;

EID: 57549098245     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05776.x     Document Type: Article

References (32)

1. Assayag K., Yakunin E., Loeb V., Selkoe D. J. Sharon R. (2007) Polyunsaturated fatty acids induce {alpha}-synuclein-related pathogenic changes in neuronal cells. Am. J. Pathol. 171, 2000 2011.
2. Bertoncini C. W., Rasia R. M., Lamberto G. R., Binolfi A., Zweckstetter M., Griesinger C. Fernandez C. O. (2007) Structural characterization of the intrinsically unfolded protein beta-synuclein, a natural negative regulator of alpha-synuclein aggregation. J. Mol. Biol. 372, 708 722.
3. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248 254.
4. Choi H. K., Won L. A., Kontur P. J., Hammond D. N., Fox A. P., Wainer B. H., Hoffmann P. C. Heller A. (1991) Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion. Brain Res. 552, 67 76.
5. Clayton D. F. George J. M. (1998) The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci. 21, 249 254.
6. Clayton D. F. George J. M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58, 120 129.
7. da Costa C. A., Masliah E. Checler F. (2003) Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. J. Biol. Chem. 278, 37330 37335.
8. Crawford G. D. Jr., Le W. D., Smith R. G., Xie W. J., Stefani E. Appel S. H. (1992) A novel N18TG2 × mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J. Neurosci. 12, 3392 3398.
9. Duda J. E., Lee V. M. Trojanowski J. Q. (2000) Neuropathology of synuclein aggregates. J. Neurosci. Res. 61, 121 127.
10. Fan Y., Limprasert P., Murray I. V., Smith A. C., Lee V. M., Trojanowski J. Q., Sopher B. L. La Spada A. R. (2006) Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. Hum. Mol. Genet. 15, 3002 3011.
11. Folch J., Lees M. Sloane Stanley G. H. (1957) A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226, 497 509.
12. Galvin J. E., Uryu K., Lee V. M. Trojanowski J. Q. (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl Acad. Sci. USA 96, 13450 13455.
13. George J. M. (2002) The synucleins. Genome Biol. 3, 1 6.
14. Hashimoto M., Rockenstein E., Mante M., Mallory M. Masliah E. (2001) Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213 223.
15. Hashimoto M., Bar-On P., Ho G., Takenouchi T., Rockenstein E., Crews L. Masliah E. (2004) Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. J. Biol. Chem. 279, 23622 23629.
16. Lee D., Lee S. Y., Lee E. N., Chang C. S. Paik S. R. (2002) Alpha-synuclein exhibits competitive interaction between calmodulin and synthetic membranes. J. Neurochem. 82, 1007 1017.
17. Maroteaux L., Campanelli J. T. Scheller R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804 2815.
18. Masliah E. Hashimoto M. (2002) Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein. Neurotoxicology 23, 461 468.
19. Mor F., Quintana F., Mimran A. Cohen I. R. (2003) Autoimmune encephalomyelitis and uveitis induced by T cell immunity to self beta-synuclein. J. Immunol. 170, 628 634.
20. Ohtake H., Limprasert P., Fan Y. et al. (2004) Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology 63, 805 811.
21. Park J. Y. Lansbury P. T. Jr. (2003) Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry 42, 3696 3700.
22. Salem S. A., Allsop D., Mann D. M., Tokuda T. El-Agnaf O. M. (2007) An investigation into the lipid-binding properties of alpha-, beta- and gamma-synucleins in human brain and cerebrospinal fluid. Brain Res. 1170, 103 111.
23. Sharon R., Goldberg M. S., Bar-Josef I., Betensky R. A., Shen J. Selkoe D. J. (2001) Alpha-synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl Acad. Sci. USA 98, 9110 9115.
24. Sharon R., Bar-Joseph I., Mirick G. E., Serhan C. N. Selkoe D. J. (2003a) Altered fatty acid composition of dopaminergic neurons expressing alpha-synuclein and human brains with alpha-synucleinopathies. J. Biol. Chem. 278, 49874 49881.
25. Sharon R., Bar-Joseph I., Frosch M. P., Walsh D. M., Hamilton J. A. Selkoe D. J. (2003b) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37, 583 595.
26. Snyder H., Mensah K., Hsu C., Hashimoto M., Surgucheva I. G., Festoff B., Surguchov A., Masliah E., Matouschek A. Wolozin B. (2005) Beta-synuclein reduces proteasomal inhibition by alpha-synuclein but not gamma-synuclein. J. Biol. Chem. 280, 7562 7569.
27. Specht C. G. Schoepfer R. (2001) Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci. 2, 11.
28. Sung Y. H. Eliezer D. (2006) Secondary structure and dynamics of micelle bound beta- and gamma-synuclein. Protein Sci. 15, 1162 1174.
29. Tsigelny I. F., Bar-On P., Sharikov Y., Crews L., Hashimoto M., Miller M. A., Keller S. H., Platoshyn O., Yuan J. X. Masliah E. (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J. 274, 1862 1877.
30. Uversky V. N., Li J., Souillac P., Millett I. S., Doniach S., Jakes R., Goedert M. Fink A. L. (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem. 277, 11970 11978.
31. Wei J., Fujita M., Nakai M., Waragai M., Watabe K., Akatsu H., Rockenstein E., Masliah E. Hashimoto M. (2007) Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies. J. Biol. Chem. 282, 28904 28914.
32. Yamin G., Munishkina L. A., Karymov M. A., Lyubchenko Y. L., Uversky V. N. Fink A. L. (2005) Forcing nonamyloidogenic beta-synuclein to fibrillate. Biochemistry 44, 9096 9107.